Candidate Genes from an FDA-Approved Algorithm Fail to Predict Opioid Use Disorder Risk in Over 450,000 Veterans
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Genetic variants used in an FDA-approved algorithm show low efficacy in predicting opioid use disorder (OUD) risk. The algorithm
Area Of Science
- Pharmacogenomics
- Computational Biology
- Clinical Genetics
Background
- The Food and Drug Administration (FDA) approved an algorithm predicting opioid use disorder (OUD) risk based on genetic factors.
- Independent validation of the clinical utility of the candidate genes within this algorithm is crucial.
Approach
- This case-control study analyzed 15 genetic variants in opioid-exposed individuals from the Million Veteran Program (MVP).
- Electronic health records (EHR) data spanning from 1992 to 2022 were used to assess the association between genetic variants and OUD diagnosis.
- Logistic regression and machine learning models evaluated the predictive performance of these variants.
Key Points
- The 15 candidate genetic variants collectively explained only 0.4% of the variation in OUD risk.
- An ensemble machine learning model utilizing these genes achieved 52.8% accuracy in predicting OUD.
- The study included over 450,000 opioid-exposed participants, with 33,669 identified as OUD cases.
Conclusions
- The candidate genes in the current FDA-approved algorithm lack sufficient efficacy for predicting OUD risk.
- The algorithm's limited predictive accuracy may result in significant false positive and negative outcomes in clinical settings.
- Development of more effective predictive models is necessary for identifying individuals at risk of OUD.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
